Alpha-Beta Technology Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alpha-Beta Technology Inc.
ConjuChem Inc.
The mission of ConjuChem is to improve the delivery profiles of existing drugs by conjugating them {in vivo} to natural protein carriers. One of its lead candidates is a peripherally-acting opioid agonist that avoids central side effects.
Have Problem? Try M&A.
M&A was the universal prescription for the medical industry in 1998 as acquisition dollar volumes hit record levels. For some, the dealmaking further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. But for nearly everyone who's using it, M&A is the easiest, if not always an effective, answer to the increasingly intractable problem of growth.
Biotechnology North of the Border
A venture-backed Canadian biotechnology industry is in its infancy, but faced with hostile capital markets, start-ups need clear exit plans. Consolidation's already started.
The PR Spin on Venture Capital
BioVentures Investors, a new fund sponsored by the Massachusetts Biomedical Initiatives Inc. is spun from a combination PR and consulting background. BioVentures managing partner Peter Feinstein is well known in the Boston area as founder and shairman of Feinstein Kean partners, a communications firm with a consulting affiliate, Kendall Strategies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice